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Summary:  Pluripotent stem cells may acquire genetic and epigenetic variants during culture 
following their derivation.  At a conference, organized by the International Stem Cell Initiative, and 
held at The Jackson Laboratory, Bar Harbor Maine, October 2016, participants discussed how the 
appearance of such variants can be monitored and minimized and, crucially, how their significance 
for the safety of therapeutic applications of these cells can be assessed.  A strong recommendation 
from the meeting was that an international advisory group should be set up to review the genetic 
and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for 
evaluating the risks that they may pose for clinical use. 
 
 
It is remarkable that only 20 years after the first report of the growth of human embryonic stem cells 
(ESCs) in vitro and just ten years after discovering that somatic cells can be reprogrammed to 
pluripotency, as induced pluripotent stem cells (iPSCs), the results of the first clinical trials of 
pluripotent stem cells (PSCs), to treat macular degeneration, have been reported (Mandai et al., 2017; 
Schwartz et al., 2015; Song et al., 2015).  Indeed, clinical trials of PSCs for a number of conditions 
including spinal cord injury, diabetes, heart disease and Parkinson’s disease, are already in progress 
or are just on the horizon  (Trounson and DeWitt, 2016).  Yet translating these initial trials into routine 
and safe therapies for the host of conditions for which PSCs offer new opportunities requires a deep 
understanding of PSC biology.  The mechanisms controlling PSC behavior during their in vitro isolation, 
genetic manipulation (if necessary), differentiation and maintenance are not fully known, and 
understanding how alterations to these behaviors could impact their fate upon engraftment into 
humans, or the appearance of potentially malignant transformed cells, is a requirement for successful 
stem cell therapeutics. 
The central question addressed at this meeting, organized by the International Stem Cell Initiative 
(ISCI), with support from the UK Regenerative Medicine Platform, was: which of the possible genetic 
and epigenetic changes that occur in PSCs in vitro might compromise the safety and efficacy of PSC-
derived products for regenerative medicine?  A diverse group of basic scientists ranging from those 
with expertise in somatic cell and cancer genetics, PSC biology, DNA synthesis and repair, epigenetics 
and apoptosis, and sensitive systems for variant detection, met with those developing and seeking to 
regulate PSC-based regenerative medicine to discuss this problem.  
The genetic changes commonly reported by numerous groups, and documented in an ISCI survey of 
well over one hundred human PSC lines (Amps et al., 2011) are non-random chromosomal alterations 
- gains of whole, or parts of, chromosomes 1, 12, 17 and 20, as well as losses of regions of chromosome 
10, 18 and 22. These changes, which apparently provide a selective growth advantage to the variant 
cells (Olariu et al., 2010), are readily detected by standard cytogenetic techniques, but only if they are 
present in over 10% of the cells in a PSC line (Baker et al., 2016).  Other methods, such as microarray 
or sequencing analysis, have also uncovered genomic changes including copy number variants (CNVs) 
and point mutations that arise during in vitro culture.  For example, a short region in the proximal part 
of chromosome 20q was amplified in 22 of 79 PSC lines with an apparently normal G-banded 
karyotype in the ISCI survey (Amps et al., 2011).  This CNV leads to overexpression of BCL2L1, with the 
consequence that these cells can escape apoptosis (Avery et al., 2013).  Mutations in p53, which were 
detected by exome sequencing of 117 human PSC lines (Merkle et al., 2017), is also expected to confer 
protection against apoptosis (Amir et al., 2017), providing a selective advantage to the cells in vitro.  
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Recurrent appearance of variants that confer a growth or survival advantage in vitro is a worrisome 
theme, particularly when the changes are known to be associated with human cancer.  Epigenetic 
changes, including erosion of X-chromosome inactivation and loss of imprinting, have also been noted 
in PSCs (Bar et al., 2017; Mekhoubad et al., 2012).  The challenge is to understand what impact these 
epigenetic changes might have on cell phenotype, stability, and growth.  One further, underexplored 
consideration, is the extent to which epigenetic changes may contribute to the likelihood of acquiring 
genetic variants in PSCs. 
With this background in mind, the assembled scientists at the ISCI meeting set out to discuss three 
overarching questions regarding the use of PSCs in clinical medicine:  1) How should cells be assayed 
to detect genetic and epigenetic variants?  2) How can the rate at which variant cells appear in cultures 
of PSCs be minimized?  3) How can the significance of the presence of particular types of variant cells 
be assessed as a prelude to ensuring their safety and efficacy in vivo? 
Detecting and minimizing the appearance of variant cells:  Screening for changes in the genome 
largely depends on established techniques, including G-band karyotyping, FISH, digital PCR, and 
microarrays, but the limits of detection, for karyotypic changes and CNVs, mean that variants may not 
be noted unless they are present in at least ~10% of the cells in a culture (Baker et al., 2016).  
Nevertheless, few studies clearly specify the limit of detection of their assays when reporting on 
particular PSC lines.  Other methods, such as single cell sequencing, now under development, could 
improve the sensitivity of detection of abnormalities in mosaic cultures.  Several meeting participants 
pointed out that genetic changes that provide a selective advantage, such as those affecting BCL2L1 
or p53 (Avery et al., 2013; Merkle et al., 2017), often become dominant in a culture in a rather short 
period of time, a factor that might mitigate some concerns over detection sensitivity.  However, 
selective advantage is likely to be context-dependent and may come into play only once the cells have 
been differentiated and/or transplanted, so that a rare variant that does not expand quickly in cultures 
of undifferentiated PSCs may still pose risk.  Minimizing the rates at which variants appear in cultures 
of PSCs during scale up and/or differentiation is a goal that might, in part, be achieved by manipulating 
the culture environment to avoid suboptimal conditions that select for variants.  This requires a 
detailed understanding of the mechanisms and dynamics by which different variant cells gain a growth 
advantage, information that is lacking in most cases. 
An alternative approach is to minimize the rate at which mutations arise in PSCs from errors in DNA 
synthesis and repair or errors in chromosome segregation at mitosis.  Unfortunately, the causes and 
mutation rates for the common variants in PSCs are unknown and difficult to assess.  Although 
considerable knowledge and expertise exists about the maintenance of genetic, and epigenetic, 
integrity in somatic cells, and in cancer, we have little knowledge about the extent to which these 
mechanisms operate in PSCs, or whether other mechanisms may apply in these unique cells.  PSCs 
certainly exhibit distinct cell cycle regulation and DNA damage responses, probably reflecting the 
position in development of the early embryonic cells to which they correspond.  Indeed, PSCs are an 
anomaly as they are the only non-transformed diploid cells that can be maintained indefinitely without 
apparent senescence. 
The potential significance of (epi)genetic variants:  It is inevitable, however, that genetic variants will 
be detected in PSC cultures and, as high resolution genetic studies continue to accrue, the challenges 
in interpreting the biological significance of a growing catalogue of genetic variation will become more 
acute.  For example, in the earlier ISCI project, we reported that CNVs found in normal, apparently 
healthy individuals surveyed in the HapMap project, also appeared during the culture of some PSCs, 
perhaps indicating unstable regions of the genome (Amps et al., 2011).  Further, otherwise healthy 
individuals do harbor subpopulations of cells containing genetic variants of unknown significance, as 
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found in studies of iPSCs derived from skin fibroblasts (Rouhani et al., 2016).  A single seemingly 
pathogenic variant is often not sufficient to lead to cellular transformation, which often requires 
multiple changes. Nevertheless, since the common recurrent changes seen in vitro apparently give a 
selective growth advantage to the undifferentiated PSCs, they might represent driver mutations 
capable of promoting teratomas or tumors of differentiated lineages following transplantation (Ben-
David et al., 2014). 
These issues were discussed side by side with presentations from various groups either conducting or 
planning PSC-based clinical trials.  Although long term therapeutic strategies with PSCs involve 
transplanting derivative differentiated cells or adult stem cells, not undifferentiated PSCs, the 
regulatory requirements for clinical trials discussed at the meeting tended to focus on demonstrating 
the absence of PSCs in the cell preparations to be transplanted.  It is indeed essential to avoid the 
accidental transplantation of undifferentiated cells but the more intractable problem is the potential 
impact on safety caused by variants that lead to malignant transformation, or to some other 
undesirable change in the particular population of cells required for therapy.  In the absence of 
knowledge about the effects of individual genetic variants on specific adult stem cells or differentiated 
cell types, existing or proposed strategies for addressing these problems include transplantation to 
easily resectable sites or encapsulation of the transplanted cells (possible in a few situations such as 
pancreatic beta-cells for treating diabetes), or the use of gene editing to introduce conditional suicide 
genes to provide a fail-safe strategy for eliminating cells after transplantation if a problem arose.  On 
the other hand, representatives of the cancer genomics community pointed out that extensive 
collaborative studies over the past decade have produced several atlases that document the bulk of 
the genetic changes that give rise to most types of human cancer.  This information should at least 
provide some perspective on which genetic alterations in PSC lines would be of greatest concern for 
therapy. 
The regulatory implications of these safety issues have been extensively discussed in Japan in relation 
to trials of iPSC-derived therapeutics, but there is no current international consensus about how they 
should be addressed.  Indeed it is important to recognize that in many cases we currently lack relevant 
information to allow an appropriate assessment of potential risks. 
Towards an International Consenus on Risk Assessment:  The recommendation of this meeting was 
to establish an international advisory group to collate and curate the information currently in hand 
while developing an international framework for evaluating the risks posed by genetic and epigenetic 
variants of PSCs for therapeutic applications.  Assessment in the long run must be context-dependent, 
taking into account patient age, disease severity, the specific cell types to be transplanted and the 
sensitivity of the techniques used to characterize the genome and epigenome of the PSCs and their 
differentiated derivatives.  Knowledge from other spheres, such as the cancer genome projects, about 
the function of genes affected in particular variants, whether they involve copy number changes, or 
mutations affecting gene regulation or function, should also be considered.  The advisory group itself 
could identify significant knowledge gaps, helping to direct research efforts into the safety assessment 
of cell therapy.  Ideally, it would also curate the genomic information from cells used for clinical trials 
as the field develops, so that a retrospective review of the phenotypic and functional behavior of the 
transplanted cells, in particular whether a given variant causes clinical problems, could be achieved.  
It was noted that the falling costs of genome-wide technologies mean that routine screening of panels 
of cell lines for subchromosomal genetic variants is now feasible.  Ultimately, given the scale of the 
issues at hand, a coordinated international consensus as to the potential risks posed by the 
appearance of (epi)genetic variants in PSCs will be necessary to ensure successful realization of the 
therapeutic potential of PSC-based therapies. 
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Figure Legend 
Some participants from the meeting explore Acadia National Park.  (Photograph courtesy of Adam 
Hirst, Stem Cell Technologies). 
